Diabetic kidney disease — diagnosis, screening, and modern four-pillar management

Diagnosis: classical diabetic kidney disease (DKD), Mogensen Stage III (incipient nephropathy — persistent albuminuria 30-300 mg/g), KDIGO stage G3a / A2.^[1]

The combination of long-standing type 2 diabetes (14 years), background retinopathy, persistent albuminuria (UACR 142 mg/g = A2, microalbuminuria), and mildly reduced eGFR (58 = G3a) is classical DKD — no atypical features (short diabetes duration, absent retinopathy, rapid decline, haematuria) to warrant biopsy. Confirm the UACR with the rule of two of three samples over three to six months.^[2]

Staging — KDIGO albuminuria/GFR heat-map. Albuminuria categories: A1 under 30, A2 (microalbuminuria) 30 to 300, A3 (macroproteinuria) over 300 mg/g. GFR categories: G1 over 90, G2 60-89, G3a 45-59, G3b 30-44, G4 15-29, G5 under 15. This patient is G3a/A2 = moderate risk for progression.^[2]

Management — modern four-pillar combination therapy (R-S-F-M mnemonic).^[3][9]

1. Pillar 1 — RAAS blockade. Switch amlodipine to (or add) an ACE inhibitor at max tolerated dose (e.g., ramipril titrated to 10 mg daily, or an ARB such as losartan titrated to 100 mg daily if ACEi not tolerated). Evidence: captopril in T1DM (Lewis 1993), IDNT/irbesartan and RENAAL/losartan in T2DM. Check creatinine and potassium at 1 to 2 weeks — a rise under 30 percent is expected and benign; over 30 percent mandates stopping and imaging for renal artery stenosis. Target blood pressure under 130/80 mmHg in albuminuric DKD.
2. Pillar 2 — SGLT2 inhibitor. Add empagliflozin 10 mg daily or dapagliflozin 10 mg daily — disease-modifying, glucose-independent kidney and cardiovascular protection down to eGFR 20 (CREDENCE, DAPA-CKD, EMPA-KIDNEY). Counsel on euglycaemic DKA, genital infections, volume status; stop in acute illness and perioperatively.^[3]
3. Pillar 3 — Finerenone (non-steroidal MRA). Once eGFR over 25 and potassium under 4.8, add finerenone 10 mg daily (eGFR 25-60) titrating to 20 mg daily at 4 weeks; monitor potassium. FIDELIO-DKD showed 18 percent kidney-outcome reduction on top of RAAS blockade.^[9]
4. Pillar 4 — Multifactorial risk reduction. Optimise glycaemic control (individualised HbA1c target around 7 percent / 53 mmol/mol — currently 8.1 percent needs intensification; add a GLP-1 receptor agonist such as liraglutide or semaglutide, second-line after SGLT2i); intensify statin (atorvastatin 40-80 mg); address weight, smoking cessation, diet (protein 0.8 g/kg/day, sodium under 2 g/day), exercise.

Continue metformin at the current dose (eGFR over 45); dose-reduce to 1000 mg/day at eGFR 30-45 and stop below 30. Consider switching gliclazide to a GLP-1 RA for additive CV/kidney benefit and weight loss. ^[2]

Lifestyle and risk-factor targets: HbA1c individualised; BP under 130/80; LDL under 1.8 mmol/L (or under 1.4 mmol/L with CVD); protein 0.8 g/kg/day; sodium under 2 g/day; aerobic and resistance exercise 150 min/week; weight target BMI 20-25; alcohol moderation; aspirin 75-100 mg only for secondary prevention. ^[2]

Follow-up and surveillance: UACR + eGFR every 3 to 6 months; HbA1c every 3 months until at target; annual retinal and foot exam; counsel on hypoglycaemia (gliclazide risk as GFR falls), sick-day rules (withhold metformin/SGLT2i during illness), and the triple-whammy risk (avoid NSAIDs). ^[2]

Escalation triggers / referral to nephrology: eGFR under 30, A3 albuminuria (UACR over 300), rapidly declining eGFR (over 5 mL/min/year), refractory hypertension, hyperkalaemia, or atypical features requiring biopsy. ^[2]

Prognosis: With early four-pillar combination therapy, the trajectory can be markedly slowed (Steno-2: a median of 7.9 years of life gained at 21-year follow-up with multifactorial intervention). Cardiovascular disease is the leading cause of death — statin and BP/SGLT2i reduce this risk. ^[2]